Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) CEO Norbert W. Bischofberger acquired 1,378,901 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were acquired at an average cost of $0.88 per share, with a total value of $1,213,432.88. Following the transaction, the chief executive officer now directly […]